Jay Baldwin admits he made mistakes with drugs from the start.
The 53-year-old former North Side resident said he was alcoholic and “played around with drugs,” including intravenous ones, in the 1970s and 1980s, but successfully underwent rehabilitation in the 1980s and hasn’t had problems since then.
But in 2003, he was diagnosed with hepatitis C, the virus spread blood to blood that settles in the liver and plagues millions of baby boomers. Mr. Baldwin’s physician told him Harvoni, made by Gilead Sciences Inc., would cure him, but his health-insurance provider likely would refuse payment for the drug. Mr. Baldwin said he was quoted a cost of $98,000 for the standard 12-week treatment.
Now married with daughters 4 and 5 years old and employed as an operations manager for a trucking company in Fairbanks, Alaska, Mr. Baldwin opted for treatment. But as his doctor predicted, Moda Health denied payment. His appeal also was denied. He could appeal two more times, but each would require “jumping through ever more hoops” with anticipation he’d be told he’s not sick enough to merit the expense.
“I kind of had my hopes up,” he said. “Geez, if you have a drug, why not get rid of the infection?”
Moda Health, a health insurance provider in Washington, Oregon and Alaska, says online that approval requires a patient to have tested positive for hepatitis C twice within six months but the patient qualifies with or without cirrhosis to receive the full treatment. In practice, here’s the problem:
“If a patient receives his medical insurance coverage through an employer, then those benefits, including the range of pharmaceuticals covered, are decided by the employer,” said Jonathan Nicholas, spokesman for Moda Health. “Just as some employees cover, say, chiropractic or naturopathic care while others opt not to, so some employers have more expansive pharmacy benefits than others.”
There was no response to follow-up questions.
Mr. Baldwin said his children are his main concern. Hepatitis C is spread blood to blood, so he hides his razor to prevent his daughters from cutting themselves with it as he strives to avoid liver disease until he and his wife raise them.
“Basically, it comes down to money, period,” Mr. Baldwin said. “But what are the costs down the road if everyone with Hep C advances to liver failure?”
David Templeton: dtempleton@post-gazette.com or 412-263-1578






Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.